glp-1 leptin New obesity drug combo uses hormone discovered 30 years ago GLP-1 Agonist for Leptin Resistance:

doi:10.1056/NEJMoa1612917 19

This means that new safety findings are continuously collected and evaluated

Thus, leptin-like insulin, represents adiposity signal inhibiting food intake by interacting with hypothalamic receptors activated through POMC and CART neuronal pathways stimulating satiety center, and reducing the activity of NPY/AgRP neurons driving the appetitive behavior

This may include your age, weight, renal function, liver function, and the presence of any comorbid conditions such as cardiovascular disease or kidney disease

No anhedonia or fatigue : A documented side effect from these meds is anhedonia, the blunting of pleasure/joy, and some users report fatigue

Rights and permissions About this article Cite this article Goldney, J., Davies, M.J